Bukkuri, Anuraag
Pienta, Kenneth J.
Austin, Robert H.
Hammarlund, Emma U.
Amend, Sarah R.
Brown, Joel S.
Funding for this research was provided by:
National Science Foundation (1746051, PHY-1734030)
Stiftelsen Längmanska Kulturfonden (BA22-0753)
Royal Swedish Academy of Sciences Stiftelsen GS Magnusons fond (MG2022-0019)
Crafoordska Stiftelsen (20220633, 20220633)
Prostate Cancer Foundation
National Cancer Institute (U54CA143803, 1U54CA193489-01A1)
National Cancer Research Institute (CA093900)
US National Science Foundation (PHY-1659940)
Princeton Catalysis Initiative
ParadOX-ERC Starting Grant (96948)
Swedish Research Council (2019-05254)
US Department of Defense (W81XWH-20-10353)
Patrick C. Walsh Prostate Cancer Research Fund
Article History
Received: 27 March 2022
Accepted: 26 July 2022
First Online: 29 July 2022
Competing interests
: KJP is a consultant for CUE Biopharma, Inc., and holds equity interest in CUE Biopharma, Inc., Keystone Biopharma, Inc. and PEEL Therapeutics, Inc. SRA holds equity interest in Keystone Biopharma, Inc. AB, RHA, EUH, and JSB declare no potential conflict of interest.